Why America’s COVID Reckoning Failed to Fix the FDA and Public Health System

The Public Health Establishment’s Failures During COVID-19

The COVID-19 pandemic laid bare the systemic failures of America’s public health institutions, eroding public trust through bureaucratic incompetence, misleading statements, and heavy-handed mandates. Agencies such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have faced criticism for decades, but none have a worse track record than the Food and Drug Administration (FDA).

Long before COVID-19, the FDA’s regulatory delays cost Americans hundreds of thousands of life years by slowing drug development. The pandemic accelerated public awareness of these issues, prompting President Donald Trump to appoint a new leadership team within the federal health apparatus—some of whom were truth-telling contrarians willing to challenge the status quo. However, the picture remains complicated, as the head of Health and Human Services has promoted controversial theories about vaccination risks with little scientific backing.

As the public health system undergoes scrutiny, the fundamental question remains: Is real reform underway, or has the system merely replaced one flawed regime with another? Regardless of political affiliation or personal integrity, no institution should have the power to dictate what individuals put into their bodies. The only viable solution is to dismantle the current regulatory healthcare apparatus and rebuild it from the ground up.

The FDA’s Regulatory Overreach: A Historical Perspective

The expansion of the FDA’s power did not begin with figures like Robert F. Kennedy Jr. or Dr. Anthony Fauci. It traces back to a 1962 law that transformed the agency from a passive reviewer of safety data into an active gatekeeper of drug approvals.

In its early years, the FDA operated under a far less restrictive framework. Its primary role was to review safety evidence submitted by drug manufacturers. If the agency did not object within 60 days, the drug could be sold over the counter. Under this system, drug companies themselves decided whether a prescription was necessary, often based on liability concerns rather than FDA mandates. Jeffrey Singer, a practicing surgeon and senior fellow at the Cato Institute, describes this as a system rooted in informed consent and voluntary exchange.

Federal control over pharmaceuticals began tightening in 1951 with the passage of the Durham-Humphrey Amendment, which restricted over-the-counter drug sales and empowered the FDA to enforce these rules. The turning point came with the European market introduction of thalidomide, a sedative prescribed to pregnant women for nausea. The drug caused severe birth defects, leading to fetal deaths either in utero or shortly after birth. This tragedy underscored the need for stricter regulations, but it also set the stage for the FDA’s growing authority over drug approvals.

Key Takeaways

• The FDA’s regulatory overreach long predates the COVID-19 pandemic, costing Americans valuable life years through delayed drug approvals.
• President Trump’s appointment of a new health leadership team introduced some reforms, but systemic issues persist.
• The FDA’s power expanded significantly after the 1962 law, transforming it from a passive reviewer into an active gatekeeper.
• The 1951 Durham-Humphrey Amendment marked the beginning of stricter federal control over pharmaceuticals, culminating in today’s restrictive regulatory environment.